|
Name |
2-(2-Acetyl-3,5-dihydroxyphenyl)acetic acid
|
Molecular Formula | C10H10O5 | |
IUPAC Name* |
2-(2-acetyl-3,5-dihydroxyphenyl)acetic acid
|
|
SMILES |
CC(=O)C1=C(C=C(C=C1O)O)CC(=O)O
|
|
InChI |
InChI=1S/C10H10O5/c1-5(11)10-6(3-9(14)15)2-7(12)4-8(10)13/h2,4,12-13H,3H2,1H3,(H,14,15)
|
|
InChIKey |
JAHPPWGWEUVLMS-UHFFFAOYSA-N
|
|
Synonyms |
Curvulinic acid; 2-(2-acetyl-3,5-dihydroxyphenyl)acetic acid; 19053-94-2; MLS000876985; 2-Acetyl-3,5-dihydroxyphenylacetic acid; SMR000440630; MEGxm0_000053; CHEMBL1609014; ACon1_002337; BDBM52758; CHEBI:183480; cid_16196973; HMS2271A04; HY-N10260; ZINC13306196; Curvulinic acid, >=95% (LC/MS-UV); NCGC00169941-01; 2-acetyl-3,5-dihydroxyphenyl acetic acid; CS-0182590; 2-(2-acetyl-3,5-dihydroxy-phenyl)acetic acid; 2-[2-ethanoyl-3,5-bis(oxidanyl)phenyl]ethanoic acid; BRD-K29161102-001-01-7
|
|
CAS | NA | |
PubChem CID | 16196973 | |
ChEMBL ID | CHEMBL1609014 |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 210.18 | ALogp: | 0.9 |
HBD: | 3 | HBA: | 5 |
Rotatable Bonds: | 3 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 94.8 | Aromatic Rings: | 1 |
Heavy Atoms: | 15 | QED Weighted: | 0.654 |
Caco-2 Permeability: | -5.389 | MDCK Permeability: | 0.00001010 |
Pgp-inhibitor: | 0.001 | Pgp-substrate: | 0.051 |
Human Intestinal Absorption (HIA): | 0.012 | 20% Bioavailability (F20%): | 0.183 |
30% Bioavailability (F30%): | 0.015 |
Blood-Brain-Barrier Penetration (BBB): | 0.069 | Plasma Protein Binding (PPB): | 74.41% |
Volume Distribution (VD): | 0.395 | Fu: | 25.65% |
CYP1A2-inhibitor: | 0.269 | CYP1A2-substrate: | 0.08 |
CYP2C19-inhibitor: | 0.037 | CYP2C19-substrate: | 0.052 |
CYP2C9-inhibitor: | 0.077 | CYP2C9-substrate: | 0.839 |
CYP2D6-inhibitor: | 0.049 | CYP2D6-substrate: | 0.177 |
CYP3A4-inhibitor: | 0.057 | CYP3A4-substrate: | 0.077 |
Clearance (CL): | 11.5 | Half-life (T1/2): | 0.943 |
hERG Blockers: | 0.016 | Human Hepatotoxicity (H-HT): | 0.124 |
Drug-inuced Liver Injury (DILI): | 0.928 | AMES Toxicity: | 0.202 |
Rat Oral Acute Toxicity: | 0.038 | Maximum Recommended Daily Dose: | 0.017 |
Skin Sensitization: | 0.778 | Carcinogencity: | 0.034 |
Eye Corrosion: | 0.736 | Eye Irritation: | 0.935 |
Respiratory Toxicity: | 0.438 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC004779 | 0.688 | D02AQY | 0.305 | ||||
ENC002382 | 0.688 | D0BA6T | 0.300 | ||||
ENC000964 | 0.680 | D08HVR | 0.288 | ||||
ENC002047 | 0.574 | D07EXH | 0.286 | ||||
ENC004672 | 0.554 | D0P7JZ | 0.286 | ||||
ENC000674 | 0.522 | D0V9EN | 0.276 | ||||
ENC002935 | 0.446 | D0U1OM | 0.270 | ||||
ENC002685 | 0.443 | D00KRE | 0.269 | ||||
ENC002155 | 0.435 | D09BHB | 0.264 | ||||
ENC000729 | 0.431 | D0J1VY | 0.260 |